Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma

Completed · Phase 2

Conditions studied: Multiple Myeloma

In brief

Primary Objective: 1\. To determine the antimyeloma effect of bortezomib after allogeneic transplantation for patients with multiple myeloma. Secondary Objective 1\. To determine the toxicity profile of bortezomib in patients with multiple myeloma undergoing allogeneic progenitor cell transplantation.

Key facts

Study ID

NCT00504634

Run by

M.D. Anderson Cancer Center

People needed

8

Starts

2004-01-01

Expected to finish

2010-05-01

Last updated by the study team

2011-09-15

Who can join

Age: any, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with multiple myeloma at least 3 months post allogeneic transplant who either failed to achieve a complete remission or are relapsing.
• Allograft performed from a related donor who is HLA-compatible (5/6 or 6/6), or class I serologic match and class II molecular matched unrelated donor).
• Zubrod Points Scale (PS) < 2, life expectancy is not severely limited by concomitant illness.
• Patient willing and able to sign informed consent.
• Patients less than 70 years of age.

You may not qualify if…

• Active Central Nervous System (CNS) disease.
• Uncontrolled acute or chronic Graft-versus-host disease (GVHD).

Where it is running

• UT MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.